However, clinical trials using MDR inhibitors have had limited success [16]; with the exception of cyclosporine that was used to inhibit P-gp in patients with low-risk acute myeloid leukemia, resulting in significant gains in overall survival and no relapse [51]. The gene discussed is PGP; the disease is acute myeloid leukemia.